Sanofi India Q2 2026: Profit Up 19% to ₹112 Cr on 6% Sales Growth
Sanofi India Limited announced its financial results for the quarter ended June 30, 2026. The company reported a 19% increase in profits before tax and exceptional items to ₹112 crores, up from ₹94 crores in Q2 2025. Total net sales grew by 6%, driven by an 8% domestic net sales increase. The Diabetes portfolio, particularly the Insulin segment, showed strong performance with double-digit growth of 14%. Profit before tax as a percentage of net sales improved to 27% from 24% in the prior year, attributed to a favorable product mix and cost management. The Board also approved the re-constitution of the Stakeholders Relationship Committee and Risk Management Committee, and noted the stepping down of the CFO.
Key Highlights
- Q2 2026 profit before tax increased 19% to ₹112 crores.
- Total net sales grew 6% to ₹415 crores (approx. 112 / 0.27).
- Diabetes portfolio, especially Insulin, delivered 14% growth.
- Profit margin improved to 27% due to cost efficiencies.
- Board approved committee re-constitutions and noted CFO stepping down.
Price Impact
More from SANOFI